

CIMZIA® (certolizumab pegol) es aprobado en la Unión Europea para el tratamiento de la psoriasis en placas de moderada a grave en adultos que son candidatos para tratamientos

(CIMZIA® actualmente no está reembolsado para el tratamiento de psoriasis en Austria, Bulgaria, Hungría, Polonia, Portugal e Irlanda.)

Los materiales de CIMZIA® contenidos en esta exposición virtual se proporcionan a HCP de todo el mundo. La información de prescripción puede variar según la aprobación local en cada país. Por lo tanto, antes de recetar cualquier producto, consulte siempre los materiales locales, como la información de prescripción y / o la ficha técnica del producto.



GL-P-CZ-PSO-2000027 Date of preparation: October 2020.

© UCB Biopharma SRL, 2020. All rights reserved.



Publicaciones recientes sobre CIMZIA® relevantes en el tratamiento de la psoriasis en placas de moderada a grave

Click para acceder a las publicaciones

1. Gordon KB, et al. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). *Br J Dermatol.* 2020. ePub ahead of print. doi:10.1111/bjd.19393.
2. Blauvelt A, et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. *Br J Dermatol.* 2020. ePub ahead of print. doi:10.1111/bjd.19314.
3. Gottlieb AB, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). *J Am Acad Dermatol* 2018;79(2):302-14 doi: 10.1016/j.jaad.2018.04.012.
4. Lebwohl M, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blinded, etanercept- and placebo-controlled study (CIMPACT). *J Am Acad Dermatol* 2018;79(2):266-76 doi: 10.1016/j.jaad.2018.04.013.
5. van der Heijde D, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo controlled trial of certolizumab pegol in psoriatic arthritis. *RMS Open* 2018;4(1):e000582.
6. Blauvelt A, et al. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. *J Eur Acad Dermatol Venereol* 2019;33:546-52 doi: 10.1111/jdv.15258.
7. Curtis JR, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and crohn's disease: a pooled analysis of 11,317 patients across clinical trials. *RMD Open* 2019;5:e000942.
8. NEW - Rosen J, Landriscina A and Friedman AJ. Psoriasis-Associated Fatigue: Pathogenesis, Metrics, and Treatment. *Cutis.* 2016;97(2):125-132.
9. NEW - Stern AF. The Hospital Anxiety and Depression Scale. *Occup Med.* 2014;64(5):393-394.

